Genmab announces statistically significant progression-free survival improvement with rinatabart sesutecan

GMAB•2026-10-23

Genmab said its Phase 3 RAINFOL-02 trial met its primary endpoint, showing statistically significant improvement in progression-free survival and overall survival for patients with platinum-resistant ovarian cancer.

Genmab announces statistically significant progression-free survival improvement with rinatabart sesutecan

1. Phase 3 trial results

Related News

RingCentral rises on upbeat FY26 profit forecast

American Express CFO tells CNBC job cuts are to “prepare for AI”

European Commission looks into starting plastics safeguard investigation

Smith & Nephew talks with J&J on orthopaedics deal fail over CEO role

TGIF data: Flash PMI, UMich